Which is the best PML risk stratification strategy in natalizumab-treated patients affected by multiple sclerosis?

C. Prezioso, M.A. Zingaropoli, M. Iannetta, D.M. Rodio, M. Altieri, A. Conte, V. Vullo, M.R. Ciardi, A.T. Palamara, V. Pietropaolo

Research output: Contribution to journalArticlepeer-review

Cite this